Drug lookup | Fillwise

INDACATEROL ACETATE & MOMETASONE FUROATE

All strengths: Limited Use — Reason for Use code 626 required; same patient cost rules

Shared coverage and patient cost rules

StatusLimited Use — Reason for Use code 626 required

Patient paysPatient pays: program not supplied; amount cannot be determined.

Other products in the same Health Canada class (R03A) — coverage varies; not interchangeable

Glycopyrronium + indacaterol + mometasone furoate (Enerzair Breezhaler): limited Use 627

Atectura Breezhaler · DIN 02498685 · 150mcg & 80mcg · Inh Pd-capsule

Limited Use — Reason for Use code 626 requiredMarketed · checked 2026-09-19

Write on scriptLU code 626 (patient must meet the criteria below)

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ontario Limited Use criteria — code 626

Reason for Use code 626 For once-daily maintenance treatment of asthma in patients aged 12 years and older with reversible obstructive airways disease. Coverage limit: LU Authorization Period: Indefinite

No interchangeable product listed in the Ontario extract

Atectura Breezhaler · DIN 02498685 Manufacturer: Novartis Pharma Canada Inc.; listing date 2022-02-28 Health Canada: Marketed since 2020-08-19 · brand ATECTURA BREEZHALER · ATC R03AK14 INDACATEROL AND MOMETASONE · form Capsule · route Inhalation · ingredients INDACATEROL (INDACATEROL ACETATE) 150 MCG, MOMETASONE FUROATE 80 MCG · company Novartis pharmaceuticals canada inc · schedule Prescription

Check this DIN again · Health Canada product record

Atectura Breezhaler: Formulary list price $1.0731/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.0731 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98847 · Verify on the e-Formulary ↗ (DIN 02498685)

Source record

DIN 02498685: Atectura Breezhaler Raw flags: sec12=Y, sec3=Y Item: 680400119; group id 714; item number 1766; lccId 00354; manufacturer id NOV Source form: Inh Pd-Cap; strength: 150mcg & 80mcg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $1.0731; ministry $1.0731 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02498685 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98847

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02498685

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Atectura Breezhaler · DIN 02498693 · 150mcg & 320mcg · Inh Pd-capsule

Limited Use — Reason for Use code 626 requiredMarketed · checked 2026-09-19

Write on scriptLU code 626 (patient must meet the criteria below)

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ontario Limited Use criteria — code 626

No interchangeable product listed in the Ontario extract

Atectura Breezhaler · DIN 02498693 Manufacturer: Novartis Pharma Canada Inc.; listing date 2022-02-28 Health Canada: Marketed since 2020-08-19 · brand ATECTURA BREEZHALER · ATC R03AK14 INDACATEROL AND MOMETASONE · form Capsule · route Inhalation · ingredients INDACATEROL (INDACATEROL ACETATE) 150 MCG, MOMETASONE FUROATE 320 MCG · company Novartis pharmaceuticals canada inc · schedule Prescription

Check this DIN again · Health Canada product record

Atectura Breezhaler: Formulary list price $1.8473/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.8473 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Source record

DIN 02498693: Atectura Breezhaler Raw flags: sec12=Y, sec3=Y Item: 680400121; group id 714; item number 1765; lccId 00354; manufacturer id NOV Source form: Inh Pd-Cap; strength: 150mcg & 320mcg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $1.8473; ministry $1.8473 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02498693 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98848

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Atectura Breezhaler · DIN 02498707 · 150mcg & 160mcg · Inh Pd-capsule

Limited Use — Reason for Use code 626 requiredMarketed · checked 2026-09-02

Write on scriptLU code 626 (patient must meet the criteria below)

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ontario Limited Use criteria — code 626

No interchangeable product listed in the Ontario extract

Atectura Breezhaler · DIN 02498707 Manufacturer: Novartis Pharma Canada Inc.; listing date 2022-02-28 Health Canada: Marketed since 2020-08-19 · brand ATECTURA BREEZHALER · ATC R03AK14 INDACATEROL AND MOMETASONE, R03AK14 INDACATEROL AND MOMETASONE · form Capsule · route Inhalation · ingredients INDACATEROL (INDACATEROL ACETATE) 150 MCG, MOMETASONE FUROATE 160 MCG · company Novartis pharmaceuticals canada inc · schedule Prescription

Check this DIN again · Health Canada product record

Atectura Breezhaler: Formulary list price $1.3419/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.3419 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Source record

DIN 02498707: Atectura Breezhaler Raw flags: sec12=Y, sec3=Y Item: 680400120; group id 714; item number 1764; lccId 00354; manufacturer id NOV Source form: Inh Pd-Cap; strength: 150mcg & 160mcg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $1.3419; ministry $1.3419 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02498707 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98849

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Other drugs in the same formulary class (68:04 Corticosteroids) and how they are covered

Matched class: 68:04 Corticosteroids

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BECLOMETHASONE DIPROPIONATE, CICLESONIDE, FLUDROCORTISONE ACETATE, FLUTICASONE FUROATE, FLUTICASONE PROPIONATE, METHYLPREDNISOLONE, METHYLPREDNISOLONE ACETATE, MOMETASONE FUROATE, TRIAMCINOLONE ACETONIDE Some products covered without a code (check the product listing): BUDESONIDE, DEXAMETHASONE, DEXAMETHASONE 21-PHOSPHATE, HYDROCORTISONE, PREDNISOLONE SODIUM PHOSPHATE, PREDNISONE 68:04 Corticosteroids

INDACATEROL ACETATE & GLYCOPYRRONIUM BROMIDE & MOMETASONE FUROATE

· 1 products · Limited Use, codes 627 · strengths: 150mcg & 50mcg & 160mcg · Inh Pd-Cap

BECLOMETHASONE DIPROPIONATE

· 2 products · General benefit · strengths: 50mcg/Metered Dose, 100mcg/Metered Dose · Aero Inh-200 Dose Pk

BUDESONIDE

· 12 products · Limited Use, codes 260, 261, 262, 263, 264 (9), General benefit (3) · strengths: 0.125mg/mL, 0.25mg/mL, 0.5mg/mL, 100mcg/Metered Dose, 200mcg/Metered Dose, 400mcg/Metered Dose · Inh Susp, Pd Inh-200 Dose Pk

CICLESONIDE

· 3 products · General benefit · strengths: 100mcg/Actuation, 200mcg/Actuation, 50mcg/Actuation · Inh-120 Dose Pk, Metered Dose Nas Sp-120 Dose Pk

DEXAMETHASONE

· 6 products · Listed, not a benefit (2), General benefit (4) · strengths: 0.5mg, 4mg · Tab

DEXAMETHASONE 21-PHOSPHATE

· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 4mg/mL · Inj Sol

FLUDROCORTISONE ACETATE

· 2 products · General benefit · strengths: 0.1mg · Tab

FLUTICASONE FUROATE

· 2 products · General benefit · strengths: 100mcg, 200mcg · Blister Pd Inh-30 Dose Pk

FLUTICASONE PROPIONATE

· 14 products · General benefit · strengths: 50mcg/Metered Dose, 125mcg/Metered Dose, 250mcg/Metered Dose, 55mcg/Actuation, 113mcg/Actuation, 232mcg/Actuation, 250mcg/Blister, 500mcg/Blister · Inh-120 Dose Pk, Pd Inh-60 Dose Pk

HYDROCORTISONE

· 5 products · General benefit (4), Temporary benefit (1) · strengths: 10mg, 20mg · Tab

METHYLPREDNISOLONE

· 1 products · General benefit · strengths: 4mg · Tab

METHYLPREDNISOLONE ACETATE

· 3 products · General benefit · strengths: 40mg/mL, 80mg/mL, 100mg/5mL · Inj Susp-1mL Pk, Inj Susp-5mL Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 68:04 and 5 more

Full class listing Related classes: 68:08 Androgens, 68:12 Contraceptives, 68:16 Estrogens, 68:20 Anti-Diabetic Agents, 68:24 Parathyroid Agents, 68:28 Pituitary Agents, 68:32 Progestogens and Oral Contraceptives, 68:36 Thyroids, 68:38 Anti-Thyroids Same formulary class, not same indication: class membership alone does not establish equivalent uses.

Other drugs whose Health Canada label lists a similar indication: asthma

From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. BUDESONIDE & FORMOTEROL FUMARATE DIHYDRATE · Limited Use, codes 330 INDICATIONS AND CLINICAL USE Asthma SYMBICORT TURBUHALER (budesonide and formoterol fumarate dihydrate) is indicated for the treatment of asthma in patients 12 years and older with reversible obstructive airways disease. PM: https://pdf.hres.ca/dpd_pm/00059997.PDF; date February 8, 2021; DIN 02245385; fetched 2026-09-10 Product monograph FLUTICASONE FUROATE & VILANTEROL · Limited Use, codes 330, 456 (1), Limited Use, codes 330 (1) Page 3 of 74 Asthma BREO ELLIPTA 100/25 mcg and BREO ELLIPTA 200/25 mcg are indicated for the once-daily maintenance treatment of asthma in patients aged 18 years and older with reversible obstructive airways disease. PM: https://pdf.hres.ca/dpd_pm/00049111.PDF; date January 7, 2019; DIN 02408872; fetched 2026-09-10 Product monograph MOMETASONE FUROATE & FORMOTEROL FUMARATE DIHYDRATE · Limited Use, codes 330 1 Indications ZENHALE® (mometasone furoate / formoterol fumarate dihydrate inhalation aerosol), is a combination of an inhaled corticosteroid (ICS) and a long-acting beta2-adrenergic agonist (LABA) indicated for: • the treatment of asthma, in patients 12 years of age and older with reversible obstructive airway disease. PM: https://pdf.hres.ca/dpd_pm/00080784.PDF; date 2025-06-09; DIN 02361752; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26

What the Health Canada label says it is for

1 INDICATIONS ATECTURA BREEZHALER (indacaterol/mometasone furoate) is a combination of a long-acting beta2- adrenergic agonist (LABA) and an inhaled corticosteroid (ICS) indicated as a once-daily maintenance treatment of asthma in adults and adolescents 12 years of age and older with reversible obstructive airways disease. ATECTURA BREEZHALER should be prescribed for patients not adequately controlled on a long-term asthma control medication, such as ICS or whose disease severity clearly warrants treatment with both a LABA and an ICS. ATECTURA BREEZHALER is not indicated for patients whose asthma can be managed by occasional use of a rapid onset, short duration, inhaled beta2-agonist or for patients whose asthma can be successfully managed by ICS along with occasional use of a rapid onset, short duration, inhaled beta2-agonist. ATECTURA BREEZHALER is not indicated for the relief of acute bronchospasm (see General). 1.1 Pediatrics Pediatrics (under 12 years of age): The safety and efficacy of ATECTURA BREEZHALER in pediatric patients less than 12 years of age has not been established, therefore, Health Canada has not authorized an indication for this age group. 1.2 … https://pdf.hres.ca/dpd_pm/00063537.PDF PM date: May 5, 2020 Source product: ATECTURA BREEZHALER; DIN 02498685; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.